De-escalating and escalating systemic therapy in triple negative breast cancer

Area of Science:

• Oncology
• Medical research

Background:

• Triple negative breast cancer (TNBC) presents the highest risk of relapse among breast cancer subtypes.
• While chemotherapy has improved outcomes, TNBC management faces challenges due to limited systemic options for therapy escalation or de-escalation.

Purpose of the Study:

• To review current treatment strategies for triple negative breast cancer.
• To discuss the role of chemotherapy, including neoadjuvant approaches and the impact of residual disease.
• To explore future directions in TNBC treatment, focusing on prognostication and targeted therapies.

Main Methods:

• Review of observational cohorts and clinical trials concerning triple negative breast cancer treatment.
• Analysis of chemotherapy regimens, including anthracycline/taxane-based and platinum incorporation in neoadjuvant therapy.
• Evaluation of treatment de-escalation in early-stage disease and post-neoadjuvant capecitabine in residual disease.

Main Results:

• Very small, node-negative TNBC (<1 cm) shows low relapse risk with minimal chemotherapy benefit.
• Anthracycline/taxane regimens are standard for node-positive disease.
• Neoadjuvant chemotherapy reduces surgical extent but lacks data for response-based de-escalation.
• Platinum incorporation improves pathological complete response (pCR) but has uncertain long-term survival impact.
• Residual disease post-neoadjuvant chemotherapy indicates a poor prognosis, with capecitabine showing a potential survival advantage.

Conclusions:

• Treatment de-escalation is feasible in select low-risk TNBC cases.
• Escalation strategies like platinum incorporation require further validation for survival benefits.
• Future TNBC research should focus on biologic prognostication and targeted non-cytotoxic therapies to address molecular heterogeneity.